CEL-SCI Corporation (AMEX:CVM) will present at the 7th Annual Vaccines: All Things Considered Conference. The presenter is Dr.Daniel Zimmerman, Ph.D., Senior Vice President Research and Development
Novartis (NYSE:NVS), Sanofi Pasteur, and Merck (NYSE:MRK) are also expected to attend.
CEL-SCI is up 11% to $1.36 on heavy volume
Douglas A. McIntyre
CEL-SCI Corporation’s (AMEX:CVM) shares have been doing well recently.
BioMedReport just did a “story” on the company reporting about that CVM will present at the the 2009 ACR/ARHP Annual Scientific Meeting.
BioMedReport says it is long the stock. Surprise, surprise.
Douglas A. McIntyre
CEL-SCI Corporation’s CEO, Geert Kersten, said his company just received FDA approval to proceed with a clinical trial of its H1N1 flu drug candidate, testing its effect on white blood cells of patients who are hospitalized. The biotech firm said it is working on the next phase of the study and is preparing the drug’s follow-up regulatory application.
The company also filed with the SEC saying it is offering to sell up to 22,000,000 shares of its common stock to investors exercising warrants previously issued by CEL-SCI.
CVM is up on heavy volume to $2.06, a 3.6% gain for the day. There is not news from the company that should cause it to trade above $1.11 where it was five days ago.
Douglas A. McIntyre
CEL-SCI Corp. (AMEX: CVM) actually looks to be the biggest of the emerging R&D companies today. The stock at one point today nearly doubled after CEO Geert Kersten says to a website the company’s work on a treatment for those already stricken with H1N1 may have significant impact on chances of survival.
The comments were made responding to questions from our friends over at BioMedReports.com, which reports CVM is in government talks over treatment. Unfortunately, that situation was given a decline in comment.
CVM has said before that it was working on a treatment to target non-mutating parts of the flu strain. Back in August, this company entered into a definitive agreement with several institutional investors in a registered direct offering to sell 9.7 million units of stock and warrants for gross proceeds of approximately $4.4 million.
Where this gets interesting is that CEL-SCI has historically been thought of as a call option or risky stock with a potential cancer treatment as it is entering a late stage oncology trial for a global Phase III trial in advanced primary head and neck cancer.
Shares have not just risen sharply. They have done so on exponential trading volume. In mid-afternoon trading, this one is up 75% at $1.62. It hit a new 52-week high today of $1.82. And as far as a 52-week low, that is down at $0.14.
JON C. OGG
September 15, 2009
Why there will be more than enough swine flu vaccine to go around (AZN, GSK, NOVN, SNY, NVAX, SVA, INO, HEB, CVM, BPAX)
With federal health officials now stepping up efforts to be sure there is enough swine flu vaccine in the U.S., opportunities may be slimmer than the Street expects for all but five companies taking the lead in delivering them.
Count on Congress to take swift action when problems hit close to home. This week, six Senate pages are sick with flu symptoms that could be H1N1, or swine flu. It just so happens that this is the week the government suggested 159 million Americans get vaccinated.
Five companies are busy ramping H1N1 vaccine production for the U.S. market, in hopes of making them available in October.
Those companies are AstraZeneca plc (NYSE: AZN), GlaxoSmithKline plc (NYSE: GSK), Novartis AG (Nasdaq: NOVN), Sanofi-Aventis SA (NYSE: SNY) and Australia’s CSL Ltd.
Many also-ran companies also are preparing vaccine candidates, in the event they are needed. Those companies include Novavax Inc. (Nasdaq: NVAX), Sinovac Biotech Ltd. (Amex: SVA), Inovio Biomedical Corp. (Amex: INO), Hemespherix Biopharma Inc. (Amex: HEB), Cel-Sci Corp. (Amex: CVM) and BioSante Pharmaceuticals Inc. (Nasd BPAX).
Despite the big ramp in swine flu vaccine production, shares of most also-ran swine flu vaccine makers have been running for months, partly in anticipation that they, too, will see top-line benefits from major Western governments buying product from them, perhaps as early as this flu season.
A look at the numbers suggests the swine flu revenue available to the also- rans may be slim.
Federal health officials this week said pregnant women, health care workers and children six months and older should be first to get vaccinated — a group that totals about 159 million people. Bullish traders long many of the also-rans note that there will not be enough to go around: Only 120 million doses of the vaccine will be made available by the five approved manufacturers by fall.
But that may be more than enough to cover everyone who wants one. Many Americans either do not have access to the vaccines, or are happy to go without them. The CDC would like 90 percent of seniors and 60 percent of high-risk adults to receive flu shots. But in 2006-2007, only 66 percent of seniors and 35 percent of targeted young adults ever received them, despite that year being an active flu season.
For those who think that adults will make sure their kids get the shot, the data suggest otherwise. Children may be the population that lags most when it comes to getting inoculations. According to the CDC, fewer than 15 percent of kids in the U.S. get all of their recommended vaccines. According to the most recent CDC data available, the most aggressive state when it comes to inoculations is Massachusetts, where more than a quarter of kids received all the shots they are supposed to have.
Access to vaccinations is only part of the problem. Among the wealthy, there are parents who are choosing not to give their kids their recommended shots, for fear of side effects. Plus, some parents believe their kids are safe, because all the other kids are getting their inoculations (which the data suggest is not the case).
True, the CDC will likely put out an all-out press blitz to get kids immunized against swine flu. But based on past efforts, an aggressive adoption rate may be 60 percent of the targeted population — or about 95 million.
Adoption among senators likely will be high. For everyone else who needs one and makes the effort to get one, there likely will be more than enough to go around — Mike Tarsala